Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | Q9HBH1 | 3/20 | 0.33 | |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21533963 | 0.85 | ALDH1A1 (0.34) | ALDH1A1MAPT | |
| SCHEMBL6799803 | 0.74 | DPP4 (0.36) | DPP4ALDH1A1TSHRPDF | |
| SCHEMBL12867291 | 0.74 | ALDH1A1 (0.38) | DPP4ALDH1A1TSHRPDF | |
| SCHEMBL24462600 | 0.74 | — | — | |
| SCHEMBL14108242 | 0.74 | ALDH1A1 (0.38) | DPP4ALDH1A1TSHRPDF | |
| SCHEMBL21325038 | 0.72 | DPP4 (0.35) | DPP4ALDH1A1TSHRPDF | |
| SCHEMBL20177027 | 0.72 | DPP4 (0.35) | DPP4ALDH1A1TSHRPDF | |
| SCHEMBL5103035 | 0.72 | DPP4 (0.53) | DPP4ALDH1A1TSHRPDFMAPT | |
| SCHEMBL4956827 | 0.72 | DPP4 (0.53) | DPP4ALDH1A1TSHRPDFMAPT | |
| SCHEMBL7608080 | 0.72 | TSHR (0.33) | DPP4ALDH1A1TSHRPDFNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174271-B2 | 6-membered uracil isosteres | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2021-11-16 | — | — | US | disclosed |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | CV6 THERAPEUTICS (NI) LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174271-B2 | 6-membered uracil isosteres | UNG, DUT, DPYD | DPP4 1451/4885ALDH1A1 972/4885TSHR 4777/4885 |
| US-20190270756-A1 | 6-MEMBERED URACIL ISOSTERES | UNG, DUT, DPYD | DPP4 1451/4885ALDH1A1 972/4885TSHR 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.